Use of a T cell-specific monoclonal antibody, T10B9, in a novel allogeneic stem cell transplantation protocol for hematologic malignancy high-risk patients

Biology of Blood and Marrow Transplantation

Volumn 10, Issue 12, 2004, Pages 858-866

  Thompson, John S ^a,b   Pomeroy, Claire ^a   Kryscio, Richard J ^a   Brown, Stephen A ^a   Reece, Donna ^a   Kramer, Rita ^a   Howard, Dianna S ^a   vanZant, Gary ^a   Humphries, Suzanne ^a   Phillips, Gordon ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b LEXINGTON VA MEDICAL CENTER   (United States)

Author keywords

Acute graft versus host disease; Anti T cell monoclonal antibody MEDI 500 (T10B9); IL 6; Regimen related toxicity; Stem cell transplantation; TNF

Indexed keywords

ACICLOVIR; ALLOPURINOL; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BUSULFAN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN; GANCICLOVIR; INTERLEUKIN 6; MEDI 500; MELPHALAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY T10B9; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD SAMPLING; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CAUSE OF DEATH; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DRUG DOSE REGIMEN; FEMALE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HERPES SIMPLEX; HIGH RISK PATIENT; HLA MATCHING; HODGKIN DISEASE; HUMAN; IMMUNOPHENOTYPING; MALE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; SURVIVAL RATE; VEIN OCCLUSION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA; LEUKOCYTE TRANSFUSION; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 10344234290     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2004.09.006     Document Type: Article

References (44)

1. H.G. Klingemann J.P. Shepherd D.E. Reece et al. Regimen-related acute toxicities: Pathophysiology, risk factors, clinical evaluation and preventive strategies Bone Marrow Transplant 14 suppl 4 1994 514-518
2. G.B. McDonald J.T. Slattery M.E. Bouvier et al Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation Blood 101 2003 2043-2048
3. H.J. Deeg T.R. Spitzer M. Couttler-Fox et al. Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis Bone Marrow Transplant 7 1991 193-198
4. H.M. Lazarus G.B. Vogelsang J.M. Rowe Prevention and treatment of acute graft-versus host disease: The old and the new. A report from the Eastern Cooperative Oncology Group (ECOG) Bone Marrow Transplant 19 1997 577-600
5. A. Baldwin A. Kingman M. Darville et al. Outcome and clinical course of 100 patients with adenovirus infections following bone marrow transplantation Bone Marrow Transplant 26 2000 1333-1338
6. R.E. Curtis P.A. Rowlings H.J. Deeg et al. Solid cancers after bone marrow transplantation N Engl J Med 336 1997 897-904
7. J.N. Barker S.M. Davies T.E. DeFor et al. Determinants of survival after human leucocyte antigen-matched unrelated donor bone marrow transplantation Br J Haematol 118 2002 101-107
8. O. Ringden M. Labopin F. Frassoni et al. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft Bone Marrow Transplant 24 1999 389-396
9. R.L. Truitt A.A. Atasoylu Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation Blood 77 1991 2515-2523
10. J.L.M. Ferrara S. Abhyankar D.G. Gilliland Cytokine storm of graft-versus-host disease: A critical role of interleukin-1 Transplant Proc 25 1993 1216-1217
11. W. Krenger G.R. Hill J.L.M. Ferrara Cytokine cascades in acute graft-versus-host disease Transplantation 64 1997 553-558
12. E. Holler H.J. Kolb A. Moller et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation Blood 75 1990 1011-1016
13. C.Q. Xun J.S. Thompson C.D. Jennings S.A. Brown M.B. Widmer Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice Blood 83 1994 2360-2367
14. 2 incompatible transplantation Transplantation 64 1997 297-302
15. E. Holler H.J. Kolb J. Mittermuller et al. Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor α (TNF-α) release in the course of pretransplant conditioning: Role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF-α (MAK 195F) Blood 86 1995 890-899
16. S. Slavin A. Nagler E. Naparstek et al. Nonmyeloablative stem cell transplantation and cell therapy as a alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 91 1998 756-763
17. M. Sykes F. Preffer S. McAfee et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-matched bone marrow transplantation Lancet 353 1999 1755-1759
18. P.D. Kottaridis D.W. Milligan R.K. Chopra et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation Blood 96 2000 2419-2425
19. A.M. Carella Cavaliere E. Lerma et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma J Clin Oncol 18 2000 3918-3924
20. L. Feinstein R. Storb Nonmyeloablative hematopoietic cell transplantation Curr Opin Oncol 13 2001 95-100
21. S. Giralt P.F. Thall I. Khouri et al. Melphalan and purine analog-containing preparative regimens: Reduced intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation Blood 97 2001 631-637
22. D. Niederwieser M. Maris J.A. Shizuru et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases Blood 101 2003 1620-1629
23. R. Or M.Y. Shapira I. Resnick et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase Blood 101 2003 441-445
24. T.H. Waid B.A. Lucas P. Amlot et al. T10B9.1A-31 anti-T-cell monoclonal antibody: Preclinical studies and clinical treatment of solid organ allograft rejection Am J Kidney Dis 14 1989 51-70
25. S.A. Brown B. Lucas T.H. Waid et al. T10B9 (MEDI-500) mediated immunosuppression: Studies on the mechanism of action Clin Transplant 10 1996 607-613
26. M. Michallet K. Bilger F. Garban et al. Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and post-transplantation factors on outcome J Clin Oncol 19 2001 3340-3349
27. P.A. McSweeney D. Niederwieser J.A. Shizuru et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects Blood 97 2001 3390-3400
28. T. Saoto Y. Kandra M. Kami et al. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma Clin Cancer Res 8 2001 1014-1020
29. J.R. Passweg S. Meyer-Monard M. Gregor et al. High stem cell dose will not compensate for T cell depletion in allogeneic non-myeloablative stem cell transplantation Bone Marrow Transplant 30 2002 267-271
30. J.A. Perez-Simon P.D. Kottaridis R. Martino et al. Nonmyeloablative transplantation with or without alemtuzumab: Comparison between 2 prospective studies in patients with lymphoproliferative disorders Blood 100 2002 3121-3127
31. S. Chakrabarti S. Mackinnon R. Chopra et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: Potential role of Campath-1H in delaying immune reconstitution Blood 199 2002 4357-4363
32. A.Y. Ho M. Kenyon I. El-Hemaidi S. Deverreux A. Paglluca G.J. Mufti Reduced-intensity allogeneic hematopoietic stem cell transplantation with alemtuzumab conditioning regimens: Survival does not plateau until after day 200 Blood 101 2003 779-780
33. R. Childs E. Clave N. Contentin et al. Engraftment kinetics after nomyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses Blood 94 1999 3234-3241
34. G.L. Phillips D.D. Davey G.A. Hale et al. Granulocyte-colony stimulating factor (G-CSF)-primed, delayed marrow harvests as a source of hematopoietic stem and progenitor cells for allogeneic transplantation Leuk Lymphoma 35 1999 303-309
35. I.F. Khouri M. Keating M. Korbling et al. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies J Clin Oncol 16 1998 2817-2824
36. D. Campana J.S. Thompson P. Amlot et al. The cytoplasmic expression of CD antigens in normal and malignant cells of the T lymphoid lineage J Immunol. 138 1987 648-655
37. L. Lamb R.S. Godder R.S. Parrish et al. Increased frequency of TCR gamma/delta T cells in disease-free survivors following T cell-depleted, partially mismatched, related bone marrow transplantation for leukemia J Hematother 5 1996 503-509
38. P.J. Henslee-Downey R.S. Parrish J.S. Macdonald et al. Combined in vitro and in vivo T lymphocyte depletion for the control of graft-versus-host disease following haploidentical marrow transplantation Transplantation 61 1996 738-745
39. M.R. Bishop P.J. Henslee-Downey J.R. Anderson et al. Long term survival in advanced chronic myelogenous leukemia following bone marrow transplantation from haploidentical donors Bone Marrow Transplant 18 1996 747-753
40. J. Wagner J.S. Thompson S. Carter et al. Impact of graft-versus-host disease (GVHD) prophylaxis on 3-year disease-free survival (DFS): results of a multi-center, randomized phase II-III trial comparing T cell depletion/cyclosporine (TCD) and methotrexate/cyclosporine (M/C) in 410 recipients of unrelated donor bone marrow (BM) Blood 100 2002 75a
41. T.H. Waid B.A. Lucas J.S. Thompson et al. Treatment of renal allograft rejection with T10B9.1A-31 or OKT3: Final analysis of a phase II clinical trial Transplantation 64 1997 274-281
42. T.H. Waid J.S. Thompson J.W. McKeown et al. Induction immunotherapy in heart transplantation with T10B9.1A-31: A phase I study Heart Lung Transplant 16 1997 913-916
43. C. Schmaltz O. Alpdogan S.J. Muriglan et al. Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation Blood 101 2003 2440-2445
44. S.A. Brown J.L. Konopa D. Zhou J.S. Thompson Expression of TNFα and F4/80 positive cells following allogeneic spleen cell transplantation Bone Marrow Transplant 33 2004 359-365